Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer

Sharad Ghamande, MD
Published: Wednesday, Nov 08, 2017



Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

The phase II GOG/NRG-0265 study sought to identify pre-treatment baseline levels of serum proteins to establish overall survival benefit for patients with persistent or recurrent metastatic carcinoma of the cervix treated with axalimogene filolisbac.
 
SELECTED
LANGUAGE


Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

The phase II GOG/NRG-0265 study sought to identify pre-treatment baseline levels of serum proteins to establish overall survival benefit for patients with persistent or recurrent metastatic carcinoma of the cervix treated with axalimogene filolisbac.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor TypesDec 31, 20181.5
Oncology Briefings™: New Frontiers in the Treatment of MSI High Endometrial CancerDec 31, 20181.0
Publication Bottom Border
Border Publication
x